BioTechniques News
Maddy Chapman
In this edition of the biotech bi-weekly, get the latest industry news – from the expansion of single-cell RNA sequencing capabilities in Cambridge, UK, and next-generation enzymatic DNA synthesis technology across India, to a free trial program allowing customers to test an advanced nuclease and the program announcement for The Antibody Series 2026 (Évora, Portugal; 16–18 September).
Products
Free trial program allows customers to test an advanced nuclease
Sino Biological (Beijing, China), a recombinant technology company, has announced the launch of SuperNuclease® Pro. This advanced nuclease is engineered to deliver enhanced nucleic acid removal performance for demanding bioprocessing and molecular diagnostic applications. To help researchers evaluate its performance in their workflows, Sino Biological is also introducing a limited-time trial program providing eligible customers with an opportunity to test the solution risk-free.
Single-cell RNA sequencing capabilities expanded in Cambridge
Novogene Europe (Cambridge, UK), a multiomics research services partner, has announced that it has expanded its single-cell RNA sequencing capability at its Cambridge Omics Centre. This expansion brings single-cell sequencing workflows built around the 10x Genomics (CA, USA) Chromium platform closer to academic, biotech and biopharma researchers in the UK. The service builds on Novogene Europe’s established single-cell expertise, including existing capability in Germany, and combines specialist project support, sequencing infrastructure and bioinformatics analysis to help researchers generate deeper biological insight from complex samples and meet growing demand for accessible single-cell transcriptomics.
eBook | RNA-seq: A peek inside the transcriptome
Enjoy news, reviews and a selection of research articles detailing how RNA sequencing is evolving to improve understanding of disease mechanisms and inform therapeutic design.
Partnerships
Expanding access to next-generation enzymatic DNA synthesis technologies across India
DNA Script (Le Kremlin-Bicêtre, France), the programmable biology company developing next-generation enzymatic DNA synthesis technologies, has announced a new distribution agreement with Imperial Life Sciences (Gurugram, India), expanding access to DNA Script’s SYNTAX® platform across India. Under the agreement, Imperial Life Sciences will distribute the SYNTAX platform throughout the country, providing local sales, technical support and application expertise to researchers seeking faster, more flexible access to high-quality single-stranded DNA oligonucleotides.
The diagnostic applications of single-cell and spatial technologies for cancer care
10x Genomics, a life science company focused on accelerating science and advancing human health, has announced a research collaboration with Lausanne University Hospital (Switzerland) to advance research in diagnostic applications of single-cell and spatial technologies for cancer care. This collaboration builds on 10x’s broader efforts to work with leading research institutions to generate the scientific evidence needed to advance future diagnostic applications of single-cell and spatial technologies.
eBook | Innovative spatial omics data collection and analysis
Dive into the innovative tools being developed to capture true single-cell spatial omics data.
People, programs and publications
Program announcement for The Antibody Series 2026
FairJourney Bio (Porto, Portugal), an antibody discovery company, has announced the program for The Antibody Series 2026, which will explore how insights from natural antibody repertoires, advances in computational design and novel engineering strategies are transforming the discovery and development of antibody therapeutics. Taking place in Évora, Portugal, 16–18 September, the three-day forum will bring together leading scientists and industry voices to discuss the latest scientific and technological advances shaping the future of the field.
New Board appointments strengthen ELRIG’s scientific leadership
ELRIG (Cambridge, UK), a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, has appointed Hitesh Sanganee and Marcus Schindler to its Scientific Advisory Board. Their appointments strengthen ELRIG’s scientific leadership and reinforce the organization’s commitment to delivering relevant, forward-thinking scientific programs that reflect the evolving needs of the drug discovery community. With their support, the organization will continue to provide delegates, exhibitors and sponsors with valuable opportunities to help drive collaboration and knowledge exchange between academia and biotech and pharma industry thought leaders.
Named a key enabling technology in the AI-driven biologics drug discovery market
Carterra® (UT, USA), a provider of high-throughput surface plasmon resonance platforms for antibody and small molecule discovery, has highlighted new research from Leerink Partners (MA, USA) identifying Carterra as a key enabling technology in the fast-growing market for AI-driven biologics drug discovery.
Bringing two-dimensional mass spectrometry to the benchtop
Researchers at the University of Warwick (UK) and spin-out company Verdel Instruments (Oxford, UK) have successfully demonstrated two-dimensional mass spectrometry (2DMS) on a benchtop instrument, making this powerful technique practical and affordable for everyday laboratory use.
Modern mass spectrometry workflows are built to reduce complexity before measurement: chromatography separates, acquisition methods filter, processing pipelines simplify. These steps are essential, but they come at a cost; information is lost, often without the analyst knowing what’s missing.
In their paper, published in Analytical Chemistry, the team provides the first demonstration of 2DMS on a commercially available quadrupole time-of-flight instrument, using an upgrade kit. They call this Q-2DMS and the paper shows how it can be used to obtain high-resolution tandem mass spectrometry data from complex mixtures without the need for chromatographic separation or mass filtering.
A US$2.1 million grant for investigating cell responses
Cancer, arthritis and diabetes can develop when cells activate the wrong genes. Yet, those failures are remarkably rare. Every second of every day, trillions of cells correctly respond to environmental stress, keeping our bodies functional.
How cells achieve that extraordinary reliability is the focus of a new US$2.1 million National Institutes of Health (MD, USA) grant awarded to University of California, Riverside (CA, USA), synthetic biologist Sonali Chaturvedi. Specifically, the research will investigate how cells maintain stability despite needing to adapt quickly to changes and stress.
This article is a collection of rehosted press releases, each linked above. Material may have been edited for length and house style. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
The post The biotech bi-weekly: next-generation enzymatic DNA synthesis, advanced nucleases and AI-driven biologics drug discovery appeared first on BioTechniques.
Powered by WPeMatico